Firms Explore First-In-Class Switches With NSURE Still In Limbo
This article was originally published in The Tan Sheet
Executive Summary
Firms are moving forward with potential first-in-class switches for chronic conditions, says Concentrics Research CEO Julie Aker. Meanwhile, FDA’s NSURE initiative offers “a lot of opportunity,” but “is still very conceptual,” the agency says.